Palladone-Sr (Hydromorphone Hydrochloride)

Hydromorphone hydrochloride is an opioid analgesic that acts on the central nervous system to relieve pain.

• Acute postoperative pain: Provides effective relief when rapid onset analgesia is required.
• Cancer-related pain: Helps control persistent pain associated with malignant disease.
• Severe chronic pain: Used when other analgesics are insufficient for long‑term pain management.

• Hydromorphone hydrochloride binds selectively to μ‑opioid receptors in the central nervous system, activating inhibitory G‑protein pathways that reduce neuronal excitability and diminish the perception of pain. This receptor engagement leads to decreased release of neurotransmitters involved in nociceptive signaling, producing analgesia.

Hydromorphone may cause a range of adverse reactions, from mild to potentially life‑threatening.

Common Side Effects

• Constipation: Reduced gastrointestinal motility leading to hard stools.
• Nausea: Sensation of queasy stomach, often accompanied by vomiting.
• Drowsiness: Sedation or feeling unusually sleepy.
• Dry mouth: Decreased salivary flow causing oral dryness.
• Dizziness: Light‑headed sensation, especially when standing quickly.
• Pruritus: Itching without rash, often localized.

Serious or Rare Side Effects

• Respiratory depression: Markedly slowed breathing that can be fatal.
• Severe hypotension: Dangerous drop in blood pressure.
• Convulsions: Seizure activity in susceptible individuals.
• Anaphylaxis: Acute allergic reaction with airway compromise.
• adrenal insufficiency: Hormonal deficiency affecting stress response.
• Cardiac arrhythmias: Abnormal heart rhythms that may require urgent care.

When prescribing Hydromorphone hydrochloride, clinicians should evaluate patient history and monitor for safety concerns.

• Assess tolerance: Determine prior opioid exposure to guide dosing.
• Monitor respiratory function: Watch for signs of slowed breathing, especially after initiation.
• Evaluate renal and hepatic function: Adjust use in patients with impaired metabolism or excretion.
• Avoid concurrent CNS depressants: Limit use with alcohol, benzodiazepines, or other sedatives.
• Educate on dependence risk: Inform patients about potential for addiction and withdrawal.
• Store below 25°C: keep in the original pack, protect from moisture.

• Hydromorhydro  
• ---
• ---  
•   
• t 
• t